Maria Moscvin

Proof that we are surviving 1st year fellowship, not only surviving but kind of thriving @UChicagoHemOnc

Kudos to @UCCancerCenter current trainees, Samuel Yates, MD, MS, Habib El-Khoury, MD and former trainee, Andrew Palmer, MD on receiving #ASH25 Abstract Achievement Award.👏👏👏 #fight4hematology @UChicagoLeuk @UCHemOncFellows @UChicagoHemOnc

@UCHemOncFellows first year fellows learning hematology things from the one and only breast oncologist Dr. Olopade at #ASH25

At #ASH25, Ben Derman, MD, ⁦(@bdermanmd⁩) emphasizes that pts with sustained deep MRD negativity and no high-risk features may safely discontinue maintenance therapy, as MRD-guided monitoring helps personalize treatment in multiple myeloma. ⁦⁩ ⁦@UChicagoHemOnc⁩

@StanfordMedRes alumni reunite at #ASH2025 🩸@Ron_Witteles @StanfordChiefs @StanfordMed

'Super excited to welcome and congratulate our incoming fellowship class. We can't wait to have you join the program next summer! #fellowshipmatch2025 @TheNRMP

@nursariipek @UCHemOncFellows A true Turkish girl spots the goodies from miles away

@MMoscvin @UCHemOncFellows I spot Trader Joe’s Turkish Baklava over there!!! Looks amazing!!

Celebrating Friendsgiving with the best first year @UCHemOncFellows crew. Grateful for this journey and these people! We missed Bukky and Shree🥹

@nursariipek @ASH_hematology @vangalenlab @BrighamWomens @YaleIM_Chiefs Yess, annual breakfast before talks as tradition

@MMoscvin @ASH_hematology @vangalenlab @BrighamWomens @YaleIM_Chiefs Omg yes so excited! Our Traditional Ash breakfast??

Late to share — MICU’s been keeping me busy! Thrilled to present our study at @ASH_hematology this year, with our paper coming out soon! Grateful for my mentors @vangalenlab @BrighamWomens and incredible support of my program @YaleIM_Chiefs!

HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to @JNJInnovMed and the huge worldwide team of investigators for making it happen. @thanosdimop @SagarLonialMD @PlasmaCellPete

I signed up for the ASH Foundation Run/Walk 5K/3K on Dec 1, 2025! runsignup.com/Race/FL/Orland… 🏃🏻‍♀️

James Watson, co-discoverer of DNA's double helix, dead at 97 reuters.com/business/healt…

Come join Nevada's first BMT/cell therapy! We are already super successful. We need another doc. I can only last so long doing Q2week call! We are helping patients in great need. I have never asked for a retweet, but colleagues please retweet. tinyurl.com/4zew3wab

Fascinating post hoc pooled analysis of BENEFIT #MMsm trial, so Isa-VRd and Isa-Rd in older ASCT-ineligible myeloma. No carfilzomib. I haven't routinely been using DOACs for VTE PPx in VRd style regimens, but perhaps I will start... 👀 [Their 💊: Apix 2.5 BID or rivarox 10 QD]

We will face a shortage of oncologists as projected cancer cases rise and number of oncologists decreasing relative to demand. 25% of oncologists are 64y and older. Number of oncologists currently on pace to meet only 29% of demand in next 12 years. Gaps will widen.

Hemonc fellows, check out this episode!! Showing your personality, not only your clinical expertise when you see patients in clinic @HemOncFellows

What a glorious fall day in Boston to join the #JimmyFundWalk to support research at @DanaFarber! Grateful that my older son wanted to walk with me to celebrate patients and their families. #staystrong #curecancer #amyloidosis

Congratulations to @DrTonyLetai on being named the new director of @theNCI. An internationally renowned researcher and oncologist, Letai has helped shape our understanding of cancer through his study of cell death. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more: bit.ly/4pRWiZy

@StanfordChiefs Emily Chu reminds us to trust yourself and your voice for #WIMMonth #WIM #WomenInMedicine